In vivo pharmacokinetic studies in SUHDL-1 tumor-bearing mice demonstrated that after intravenous injection of 89Zr-anti-CD25 IgG, plasma activity represented three fourths to two thirds of whole blood activity with highly similar exponential clearance rates and half-lives. The gene discussed is IL2RA; the disease is neoplasm.